2016 to 2020 Saw Rise in Against-Medical-Advice Discharges for Opioid Admissions
By Lori Solomon HealthDay Reporter
WEDNESDAY, Jan. 3, 2024 -- Before-medically-advised (BMA) discharges increased to one in six patients from 2016 to 2020 for admissions with opioid use disorder (OUD) and an injection-related infection, according to a research letter published in the Dec. 4 issue of the Journal of the American Medical Association.
Ashish P. Thakrar, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined BMA discharge trends for opioid-related admissions (2016 to 2020). The analysis included admissions with OUD and an injection-related infection.
The researchers found that during the study period, the annual BMA discharge rate for admissions with OUD and an injection-related infection increased from 9.3 to 17.0 percent (annual growth rate, 1.8 percent). For comparison, for nonopioid mental health or substance use admissions, the BMA rate increased only marginally, from 3.1 to 3.5 percent (annual growth rate, 0.1 percent). The proportion of BMA discharges occurring before the third day did not significantly change for all opioid-related admissions (63.6 versus 62.1 percent; annual growth rate, −0.3 percent), but increased for admissions with OUD and an injection-related infection (42.6 versus 48.0 percent; annual growth rate, 1.1 percent).
"Among admissions with OUD and an injection-related infection, a higher proportion of BMA discharges occurred before the third day in 2020 versus 2016, suggesting that untreated withdrawal might contribute to increasing BMA discharges in this cohort," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.